Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$355,887.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Southpoint Capital Advisors Lp sold 26,900 shares of the business’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of C$13.23, for a total transaction of C$355,887.00. Following the completion of the sale, the insider directly owned 4,050,314 shares in the company, valued at approximately C$53,585,654.22. This represents a 0.66% decrease in their position.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.07, for a total transaction of C$256,237.35.
• On Thursday, October 9th, Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$12.89, for a total transaction of C$265,650.01.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock opened at C$12.30 on Monday. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$13.83. The stock has a market cap of C$342.33 million, a price-to-earnings ratio of -27.33 and a beta of 2.48. The company’s fifty day moving average is C$12.20 and its 200 day moving average is C$10.75.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.